Health Care & Life Sciences » Pharmaceuticals | Kaken Pharmaceutical Co. Ltd.

Kaken Pharmaceutical Co. Ltd. | Ownership

Companies that own Kaken Pharmaceutical Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Norges Bank Investment Management
1,049,199
2.17%
427,621
0.01%
12/31/2017
Azimut Capital Management SGR SpA
950,500
1.96%
176,900
0.76%
06/30/2017
The Vanguard Group, Inc.
831,257
1.72%
7,600
0%
07/31/2018
Nomura Asset Management Co., Ltd.
816,599
1.69%
27,221
0.02%
07/31/2018
Schroder Investment Management Ltd.
403,200
0.83%
-16,800
0.01%
07/31/2018
Daiwa Asset Management Co. Ltd.
332,200
0.69%
-49,200
0.02%
07/31/2018
Tokio Marine Asset Management Co., Ltd.
308,400
0.64%
177,600
0.24%
07/24/2017
BlackRock Fund Advisors
303,900
0.63%
100
0%
09/06/2018
Nikko Asset Management Co., Ltd.
287,298
0.59%
1,098
0.01%
09/03/2018
Nordea Investment Management AB (Denmark)
192,399
0.4%
-78,503
0.01%
08/31/2018

About Kaken Pharmaceutical Co.

View Profile
Address
2-28-8 Honkomagome
Tokyo Tokyo 113
Japan
Employees -
Website http://www.kaken.co.jp
Updated 07/08/2019
Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its operations are carried out through the following business divisions: Pharmaceuticals and Medical Devices, Agrochemicals and Animal Health Products, Overseas Activity, Research & Development, and Licensing Opportunities. The Pharmaceuticals and Medical Devices division offers artz(anti-osteoarthritis), clenafin (topical onychomycosis treatment product), seprafilm (anti-adhesive absorbent barrier), lipidil (anti-hyperlipidemia product), fiblast spray (wound-healing product), mentax (anti-trichophyton product) and generic drugs.